Clinical Trial Update: A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

This is a long-term extension Phase 3 study of subcutaneous tocilizumab (RoActemra/Actemra) in adults with moderate to severe rheumatoid arthritis. The trial re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• RoActemra/Actemra (tocilizumab) (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2016-08-29